Coverage / PRTA / Trade Card

PRTA

Prothena Corporation PLC

OPPORTUNISTIC BUY Analysis generated 2026-10-04 Market data as of 2026-11-12 Market data 3 days old USD 8.23 Healthcare - BiotechnologyAWAIT ENTRY
ACTIONABLEMethodology gates passed
62

Position levels

Currenttoday
USD 8.23
Buy <=wait / entry
USD 7.63
Trim >=take some off
USD 12.50
Thesis breakA failed Phase 3 or Phase 2 read-out on a partner-led programme, or a regulatory...
-

Scenario-weighted conviction

ProbabilityScoreContribution
Bull case29%100 / 10029.0
Base case50%62 / 10031.0
Bear case21%10 / 1002.1
Weighted conviction62 / 100 - OPPORTUNISTIC BUY

Top risks

  • Board authorized up to $100 million share repurchase plan
  • Roche initiated Phase 3 PARAISO trial evaluating prasinezumab in early-stage Parkinson's disease
  • Novo Nordisk initiated Phase 3 CLEOPATTRA trial evaluating coramitug in ATTR amyloidosis with cardiomyopathy
Read full report →

Research is for informational purposes only. Not financial advice. All analysis reflects the date of publication.

\n